Digest Network Come funziona
Network
/
Società
Tu
Non verificato

Turn Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteSanità

5 comunicati stampa

Guarda tutti i comunicati
07/07/2026
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Web e Social Network
Telefonia e Varie
Industria
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
Fonte
Turn Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/07/2026
Web e Social Network
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
Fonte
Turn Therapeutics, Inc.
Emittente
Business Wire
1.00
0
24/03/2026
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
Fonte
Turn Therapeutics, Inc.
Emittente
Business Wire
1.00
0
17/02/2026
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
Fonte
Turn Therapeutics, Inc.
Emittente
Business Wire
1.00
0
12/01/2026
Eventi
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
Fonte
Turn Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0